Ablation, Pancreatic Neoplasms
Conditions
Brief summary
Pancreatic carcinoma (PC) is the deadliest malignant tumors worldwide. Surgical resection is one of the most effective methods for the treatment of PC, but the resectable rate is less than 20% among the patients with PCs, and the recurrent and metastatic rate is more than 80% in two years after resection. Ablation has been confirmed one of the most effective methods for solid tumors by recent twenty years and proven to be a radical treatment similar to the surgical resection for the clinical applications of hepatic and renal tumors at early clinical staging in the internationally guidelines. The purpose is to explore the efficacy and safety of microwave ablation in the treatment of pancreatic cancer in combination with systematic therapy.
Detailed description
Pancreatic carcinoma (PC) is the deadliest malignant tumors worldwide. Surgical resection is one of the most effective methods for the treatment of PC, but the resectable rate is less than 20% among the patients with PCs, and the recurrent and metastatic rate is more than 80% in two years after resection. Furthermore, it is difficult to achieve tumoral complete responses by traditional therapies including chemotherapy, radiotherapy and transarterial embolization. Ablation has been confirmed one of the most effective methods for solid tumors by recent twenty years and proven to be a radical treatment similar to the surgical resection for the clinical applications of hepatic and renal tumors at early clinical staging in the internationally guidelines. However, the published clinical practices on the thermal ablation of PCs with large-scale cases are rare. One of the most important reasons for this originates from the extreme complexity and difficult regulation of the temperature distribution in tumors during thermal ablation because of the own characteristics of PCs, including highly invasive growth without tumoral capsules, high proportion of the interstitial fiber tissue, and the unusual blood perfusion because of extremely chaotic microvascular structures. The purpose is to explore the efficacy and safety of microwave ablation in the treatment of pancreatic cancer in combination with systematic therapy.
Interventions
PROCEDURESystematic Therapy Combined With Microwave Ablation
Patients with unresectable pancreatic cancer were included for laboratory examination, and quality of life and pain scores were recorded. The experimental group underwent microwave ablation first, followed by chemotherapy according to the guidelines; The control group received the same chemotherapy. Record the use of chemotherapy drugs and the occurrence of adverse events. Follow up will be conducted at 30 days, 90 days, and 180 days after chemotherapy to evaluate pancreatic function and quality of life.
Sponsors
Chinese PLA General Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Inoperable pancreatic cancer * Age from 18 to 80 * PS score from 0 to 3 * Clear pathological diagnosis
Exclusion criteria
* Severe coagulation dysfunction * Individuals with severe heart, lung, liver, and kidney dysfunction * Individuals with acute or active infectious lesions in any part of the body * Researchers believe that there are any other factors that are not suitable for inclusion or that affect the participation of participants in the study * Psychological health issues that hinder this experiment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 30, 90, and 180 days after the end of the last chemotherapy | Time from receiving treatment to death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain relief rate | 30, 90, and 180 days after the end of the last chemotherapy | Pain relief before and after treatment |
Contacts
Primary ContactPing Liang
Outcome results
None listed